VX-765: Selective Oral Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is an orally absorbed, potent and selective inhibitor of caspase-1, central to the processing of IL-1β and IL-18 in inflammatory responses (APExBIO product page). The compound specifically suppresses pyroptosis and related cytokine release in preclinical models, without affecting TNFα, IL-6, or IL-8 secretion (Yuan et al., 2022). Its active metabolite, VRT-043198, is responsible for in vivo efficacy. VX-765 has been benchmarked in models of rheumatoid arthritis, skin inflammation, and HIV-associated CD4 T-cell death. Its selectivity and solubility profile make it a preferred research tool for dissecting the caspase-1/ICE pathway.

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease involved in the maturation of pro-inflammatory cytokines, including IL-1β and IL-18 (Yuan et al., 2022). Activation of the NLRP3 inflammasome leads to caspase-1 activation, which mediates pyroptosis—a form of programmed cell death distinct from apoptosis and necrosis (Pyrene Azide). Pyroptosis is implicated in endothelial dysfunction, atherosclerosis, and macrophage cell death during infection. Excessive caspase-1 activity contributes to chronic inflammation and tissue damage seen in autoimmune and infectious diseases. Small molecule inhibitors of caspase-1, such as VX-765, enable targeted study of these processes and potential therapeutic modulation.

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally bioavailable prodrug. It is rapidly converted in vivo to its active metabolite, VRT-043198 (APExBIO). VRT-043198 reversibly inhibits caspase-1 by binding to the enzyme's active site, thereby preventing the cleavage of pro-IL-1β and pro-IL-18 into their mature, secreted forms (Tofacitinib.biz). VX-765 exhibits high selectivity for caspase-1 over other caspase family members, minimizing off-target effects on apoptosis or necroptosis pathways. In cellular models, VX-765 inhibits IL-1β and IL-18 release but does not significantly impact IL-1α, TNFα, IL-6, or IL-8 production (Yuan et al., 2022). This selectivity is critical for dissecting caspase-1-specific inflammatory signaling.

Evidence & Benchmarks

• VX-765 significantly suppresses H₂O₂-induced pyroptosis in human umbilical vein endothelial cells at 10 μM for 1 hour (Yuan et al., 2022, DOI).
• Oral administration of VX-765 reduces IL-1β and IL-18 secretion in mouse models of rheumatoid arthritis and dermatitis (APExBIO).
• VX-765 prevents CD4 T-cell pyroptosis in HIV-infected ex vivo lymphoid tissues in a dose-dependent manner (AIP-1.com).
• In biochemical assays, VX-765 inhibits caspase-1 activity using the suc-YVAD-pNA substrate with nanomolar IC₅₀ values (APExBIO).
• VX-765 exhibits high solubility in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonic assistance); insoluble in water (APExBIO).

For comparison, PHA-793887.com discusses broader cell death signaling, while this article focuses specifically on caspase-1–mediated pyroptosis and selective cytokine modulation by VX-765.

Applications, Limits & Misconceptions

VX-765 is primarily used in research models of inflammation, autoimmune disease, and infectious disease. Its oral bioavailability and selectivity make it suitable for in vivo and in vitro studies of caspase-1/ICE signaling (INCB018424.com). The compound is a key tool in elucidating the role of pyroptosis in endothelial and immune cell biology. VX-765 also enables mechanistic dissection of IL-1β/IL-18-driven pathology and is used in caspase-1 activity assays in biochemical workflows.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit other caspase family members (e.g., caspase-3 or -8) at pharmacologically relevant concentrations.
• It does not modulate cytokines such as TNFα, IL-6, or IL-8, so it is not a pan-cytokine inhibitor.
• VX-765 is not water soluble and requires DMSO or ethanol for dissolution; improper solvent use affects assay reliability.
• Long-term solution storage is not recommended; VX-765 solutions should be prepared fresh for each experiment.
• In vivo, efficacy is dependent on metabolic conversion to VRT-043198; use in species with altered metabolism may affect results.

See Pyrene Azide for a foundational overview of selective caspase-1 inhibition; this article updates with recent data on HIV-associated pyroptosis and solubility guidelines.

Workflow Integration & Parameters

For cell-based assays, VX-765 is typically used at 10–25 μM for 0.5–2 hours, dissolved in DMSO (final DMSO concentration ≤0.1%). For animal studies, oral gavage is the standard route, with dosing regimens adjusted for species and experimental context. For biochemical caspase-1 activity assays, VX-765 is added to reaction buffers containing the suc-YVAD-p-nitroanilide substrate. Storage desiccated at -20°C is recommended, with working solutions prepared immediately before use. The A8238 kit from APExBIO provides high-purity material suitable for both in vitro and in vivo research (product page).

Related literature, such as AIP-1.com, reviews VX-765's role in inflammatory signaling; this article extends coverage with workflow parameters and pitfalls for bench scientists.

Conclusion & Outlook

VX-765 is a benchmark selective oral caspase-1 inhibitor that enables precise investigation of the inflammasome pathway, cytokine modulation, and pyroptosis in disease models. Its specificity, pharmacokinetic properties, and robust solubility in organic solvents make it a preferred research tool. Ongoing studies are expanding the utility of VX-765 to additional models of chronic inflammation and infectious disease. For up-to-date specifications and ordering, refer to the APExBIO VX-765, Caspase-1 inhibitor, potent and selective product page.